Therapeutic vaccines against melanoma and colorectal cancer
- PMID: 11257394
- DOI: 10.1016/s0264-410x(00)00491-6
Therapeutic vaccines against melanoma and colorectal cancer
Abstract
Our overall strategy is to develop multivalent recombinant vaccines capable of eliciting broad immune responses in patients with malignant melanoma or colorectal cancer. We report herein results from initial studies conducted in cancer patients to evaluate the effect of intratumoral administration of recombinant canarypox viruses carrying cytokine genes. Our current focus is on the induction of tumor-specific T-cell responses using a prime/boost immunization schedule with a unique vector system derived from the canary pox virus called ALVAC, in which we incorporate genes encoding Tumor Associated Antigens (TAAs) of interest. Clinical studies in colorectal cancer evaluating an ALVAC CEA candidate vaccine have shown that this approach is safe and can induce tumor-specific T cell responses. Additional clinical studies evaluating candidate vaccines against melanoma and colorectal cancer, targeting either the gp100, Mage 1, Mage 3 or p53 molecules are ongoing.
Similar articles
-
Recombinant cancer vaccines based on viral vectors.Dev Biol (Basel). 2004;116:117-22; discussion 133-43. Dev Biol (Basel). 2004. PMID: 15603188
-
[Antitumor vaccines: conception, development and evaluation in humans].Ann Pharm Fr. 2002 Jul;60(4):253-9. Ann Pharm Fr. 2002. PMID: 12378152 Review. French.
-
Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.Vaccine. 1997 Apr-May;15(6-7):759-68. doi: 10.1016/s0264-410x(96)00238-1. Vaccine. 1997. PMID: 9178479
-
Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells.J Immunol. 2001 Aug 1;167(3):1795-802. doi: 10.4049/jimmunol.167.3.1795. J Immunol. 2001. PMID: 11466405
-
Recombinant viruses as a tool for therapeutic vaccination against human cancers.Immunol Lett. 2000 Sep 15;74(1):11-25. doi: 10.1016/s0165-2478(00)00244-3. Immunol Lett. 2000. PMID: 10996623 Review.
Cited by
-
The genome of canarypox virus.J Virol. 2004 Jan;78(1):353-66. doi: 10.1128/jvi.78.1.353-366.2004. J Virol. 2004. PMID: 14671117 Free PMC article.
-
Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract.World J Gastroenterol. 2003 Mar;9(3):495-8. doi: 10.3748/wjg.v9.i3.495. World J Gastroenterol. 2003. PMID: 12632504 Free PMC article.
-
[Immunization: leaps into the future. The vaccinology at the beginning of the 21th century (II)].Aten Primaria. 2002 Jun 30;30(2):130-3. doi: 10.1016/s0212-6567(02)78984-1. Aten Primaria. 2002. PMID: 12106566 Free PMC article. Review. Spanish.
-
Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells.Vaccine. 2008 Sep 15;26(39):5004-13. doi: 10.1016/j.vaccine.2008.07.050. Epub 2008 Aug 6. Vaccine. 2008. PMID: 18691624 Free PMC article.
-
Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system.J Virol. 2002 Feb;76(4):1649-62. doi: 10.1128/jvi.76.4.1649-1662.2002. J Virol. 2002. PMID: 11799160 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
